Widely used:Recently Viewed
Clear AllValue Research Rating
Quality Score 
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Market cap
₹907 Cr
Revenue (TTM)
₹598 Cr
Net Profit (TTM)
₹31 Cr
ROE
0 %
ROCE
101.1 %
P/E Ratio
29.7
P/B Ratio
15.3
Industry P/E
37.85
EV/EBITDA
13.4
Div. Yield
0 %
Debt to Equity
2.7
Book Value
₹18.1
EPS
₹9.3
Face value
10
Shares outstanding
32,770,498
CFO
₹382.11 Cr
EBITDA
₹160.83 Cr
Net Profit
₹52.40 Cr
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Wanbury
| -4.7 | -8.8 | 22.6 | 72.5 | 66.9 | 63.6 | 15.7 |
|
BSE Healthcare
| -4.6 | 0.9 | 5.1 | 17.0 | 27.1 | 21.6 | 10.3 |
|
BSE Small Cap
| -4.4 | 1.8 | 13.8 | 1.9 | 29.5 | 33.7 | 17.0 |
|
Company
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|---|---|---|---|---|---|---|---|
|
Wanbury
| 127.0 | 157.2 | -41.5 | 71.1 | 150.1 | -9.3 | -56.3 |
|
BSE Small Cap
| 29.0 | 47.5 | -1.8 | 62.8 | 32.1 | -6.8 | -23.4 |
|
BSE Healthcare
| 43.1 | 37.0 | -12.1 | 20.9 | 61.4 | -3.5 | -5.9 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Wanbury
|
277.4 | 907.4 | 597.8 | 30.5 | 10.2 | 62.3 | 29.7 | 15.3 |
| 853.3 | 7,739.3 | 2,115.1 | 272.4 | 17.8 | 14.2 | 28.4 | 3.9 | |
| 1,132.2 | 9,257.3 | 1,006.9 | 160.4 | 20.4 | 12.6 | 58.3 | 7.1 | |
| 542.7 | 8,529.2 | 4,118.2 | 343.8 | 7.6 | 10.7 | 25.2 | 2.8 | |
| 487.4 | 11,813.1 | 4,481.6 | 501.5 | 16.1 | 13.4 | 23.6 | 3.2 | |
| 359.5 | 4,437.0 | 1,859.8 | 90.8 | 10.4 | 7.4 | 48.9 | 3.5 | |
| 847.6 | 4,854.7 | 1,243.7 | 128.3 | 13.0 | 13.8 | 37.9 | 5.1 | |
| 1,014.9 | 2,505.8 | 356.3 | 100.9 | 25.0 | 13.3 | 24.8 | 3.2 | |
| 156.7 | 5,075.5 | 71.8 | -342.5 | -467.5 | -- | -- | -23.4 | |
| 936.2 | 2,786.6 | 293.0 | -56.7 | -16.7 | -29.5 | -- | 8.9 |
2 min read•By Research Desk
Wanbury Limited manufactures and sells formulations and active pharmaceutical ingredients (API) in India and internationally. The company offers formulations for gynecology, orthopedics, hematinic, anti-diabetic, nutraceuticals, gastro intestinal,... stroke surgery, antibiotics, cough and cold solutions, anti-inflammatory, analgesics, and general practitioner. It also provides API products for anti-diabetic, anti-analgesic, anti-depressant, anti-histaminic, anti-inflammatory, anti-arthritis, anti-thrombotic, anti-epileptic, and anti-hypertensive therapeutic areas. The company was formerly known as Pearl Organics Limited and changed its name to Wanbury Limited in 2004. Wanbury Limited was incorporated in 1988 and is headquartered in Navi Mumbai, India. Read more
Incorporated
1988
Chairman
--
Managing Director
--
Headquarters
Navi Mumbai, Maharashtra
Website
Our rating system has guided millions of investors in the past 20 years.
Annual Reports
The total asset value of Wanbury Ltd stood at ₹ 414 Cr as on 31-Mar-25
The share price of Wanbury Ltd is ₹277.35 (NSE) and ₹276.90 (BSE) as of 20-Jun-2025 IST. Wanbury Ltd has given a return of 66.91% in the last 3 years.
Wanbury Ltd has a market capitalisation of ₹ 907 Cr as on 20-Jun-2025. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Wanbury Ltd is 15.31 times as on 20-Jun-2025, a 330% premium to its peers’ median range of 3.56 times.
The P/E ratio of Wanbury Ltd is 29.72 times as on 20-Jun-2025, a 21% discount to its peers’ median range of 37.85 times.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Wanbury Ltd and enter the required number of quantities and click on buy to purchase the shares of Wanbury Ltd.
Wanbury Limited manufactures and sells formulations and active pharmaceutical ingredients (API) in India and internationally. The company offers formulations for gynecology, orthopedics, hematinic, anti-diabetic, nutraceuticals, gastro intestinal, stroke surgery, antibiotics, cough and cold solutions, anti-inflammatory, analgesics, and general practitioner. It also provides API products for anti-diabetic, anti-analgesic, anti-depressant, anti-histaminic, anti-inflammatory, anti-arthritis, anti-thrombotic, anti-epileptic, and anti-hypertensive therapeutic areas. The company was formerly known as Pearl Organics Limited and changed its name to Wanbury Limited in 2004. Wanbury Limited was incorporated in 1988 and is headquartered in Navi Mumbai, India.
The promoters of Wanbury Ltd are EXPERT CHEMICALS (INDIA) PVT LTD and KINGSBURY INVESTMENTS INC.. They collectively own 39.76 per cent of the total equity. The chairman of the company is
The promoters of Wanbury Ltd have pledged 30.51% of the total equity as on Mar-25.
Some of the close peers are:
| Company | Market Cap(₹ Cr) |
|---|---|
|
11,813
|
|
|
9,257
|
|
|
8,529
|
|
|
7,739
|
|
|
5,076
|
|
|
4,855
|
|
|
4,437
|
|
|
2,787
|
|
|
2,506
|
| Wanbury Ltd. | Ratios |
|---|---|
|
Return on equity(%)
|
62.3
|
|
Operating margin(%)
|
10.25
|
|
Net Margin(%)
|
5.06
|
|
Dividend yield(%)
|
0
|
Yes, TTM profit after tax of Wanbury Ltd was ₹31 Cr.
₹-3.75
(
